This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds

This study is currently recruiting participants.
See Contacts and Locations
Verified February 2017 by Florida Hospital
Sponsor:
Information provided by (Responsible Party):
Florida Hospital
ClinicalTrials.gov Identifier:
NCT02531607
First received: February 11, 2015
Last updated: February 13, 2017
Last verified: February 2017
  Purpose
This is a non-randomized natural history protocol in which patients undergoing surgery or endoscopy for suspected/ diagnosed pancreaticobiliary strictures are assigned to a) control (chronic pancreatitis, no pancreatic neoplasm, primary sclerosing cholangitis), b) non-carcinoma (bile duct stones, papillary stenosis, ), c) carcinoma non-pancreatic (ampullary and distal bile duct or cholangiocarcinoma) and d) pancreatic ductal adenocarcinoma (pancreatic cancer.

Condition Intervention
Pancreatic Neoplasms Other: blood and bile

Study Type: Observational
Study Design: Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds Biomarkers in Bile and Serum in the Diagnosis of Malignant Biliary Strictures

Resource links provided by NLM:


Further study details as provided by Florida Hospital:

Primary Outcome Measures:
  • Sensitivity and specificity of biomarkers in the diagnosis of cancer [ Time Frame: one year ]
    Comparative efficacy of biomarkers, brush cytology, fluorescence in situ hybridization (FISH), carbohydrate antigen 19-9 (CA 19-9) and biliary and blood biomarkers (lipidomics, proteomics, micro RNAs and VOCs) in the diagnosis of malignancy.


Secondary Outcome Measures:
  • Medical Record Review [ Time Frame: one year ]
    Subjects who do not have a differential diagnosis of either cancer, biliary or pancreatic disease at the time of the index ERCP will have their medical record reviewed quarterly for new diagnoses or procedures related to pancreatic malignancy, peri-ampullary malignancy, biliary disease, or pancreatic disease.


Biospecimen Retention:   Samples With DNA
bile and blood

Estimated Enrollment: 500
Study Start Date: June 2015
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: blood and bile
    20ml of blood will be obtained from consented participants. 5ml of bile will be collected during the endoscopic procedure.
Detailed Description:

Visit 1 for all participants will consist of going over the Informed Consent form and talking with the patient about the study. If the patient agrees to participate, he/she will be asked to sign the form, and a copy will be given to him/her for his/her records. This will be conducted during the day of the endoscopic procedure before the participant is under anesthesia.

Consented participants will have 20ml of blood collected via venipuncture of peripheral vein drawn by the endoscopy unit staff during their endoscopy procedure. The blood will be collected into heparinized vacutainers and immediately labeled with study specific code identifier and placed at 4⁰C until processed (within 24hr).

For clinical purposes, tissue may be removed during the endoscopic procedures. This tissue will be given to the Diagnostic Pathology personnel associated with the case for analysis. The diagnostic sample will be processed for DP use and stored in the DP active archives. No additional tissue will be taken solely for the purposes of this research study. However, if DP approves the use of the remaining clinical diagnostic, small cores or slides will be taken after the diagnostic use from the approved paraffin-embedded tissue blocks for use in comparison/confirmatory analyses to the bile and blood analyses done for this research project.

During the endoscopic procedures a 5ml aspiration of bile fluid will be collected for this study with the endoscopic instrument. The fluid will be transferred to a sterile tube, sealed, and placed at 4⁰C until processed (within 24hr). Both blood and fluids samples will be transferred to TRI R&D for analysis.

Follow Up (follow up will take place for all groups listed on page 7 of the protocol under "Study Design" with the exception of group B) 2 weeks post procedure- A member of the research staff will call the participant to assess for any complications Periodic medical record auditing for outcome data will be collected every three months for up to 1 year after enrollment.

One year post procedure- A member of the research staff will call the participant to assess for any complications

  Eligibility

Ages Eligible for Study:   19 Years to 95 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients scheduled for ERCP at CIE
Criteria

Inclusion Criteria:

Screening Criteria for Potential Participants in the Study

  1. Age: ≥18years old
  2. Treatment: scheduled for clinical reason to undergo an ERCP (Endoscopic retrograde cholangiopancreatography) at CIE
  3. Suspected of having biliary or pancreatic disease other than cancer (chronic pancreatitis, benign biliary strictures, post-liver transplant strictures, common bile duct stones, sphincter of Oddi dysfunction or suspected of having pancreatic or peri-ampullary malignancy (including pancreatic ductal adenocarcinoma, distal cholangiocarcinoma, ampullary carcinoma, duodenal, carcinoma
  4. Clinical or image data suggestive of pancreatic disease or the need for gastrointestinal or pancreatic inspection.
  5. Willing and mentally able to provide consent

Exclusion Criteria:

  1. Age: <18years old
  2. Pregnant women
  3. Post-bariatric surgery, hepaticojejunostomy and Bilroth II patients undergoing ERCP.
  4. Not scheduled for endoscopic procedures for clinical reasons
  5. No clinical or image data suggestive of need for clinical intervention (Endoscopy)
  6. Not willing or able to sign informed consent..
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02531607

Contacts
Contact: Uday Navaneethan, MD 407-303-5503 udayakumar.navaneethan.MD@flhosp.org
Contact: Shyam Varadarajulu, MD 4073039736 shyam.varadarajulu.md@flhosp.org

Locations
United States, Florida
Florida Hospital Center for Interventional Endoscopy Recruiting
Orlando, Florida, United States, 32803
Contact: Uday Navaneethan, MD    407-303-2879    uday.navaneethan.MD@flhosp.org   
Contact: Shyam Varadarajulu, MD    407-303-9736    shyam.varadarajulu.MD@flhosp.org   
Sponsors and Collaborators
Florida Hospital
Investigators
Principal Investigator: Uday Navaneethan, MD Florida Hospital
  More Information

Responsible Party: Florida Hospital
ClinicalTrials.gov Identifier: NCT02531607     History of Changes
Other Study ID Numbers: 649074
Study First Received: February 11, 2015
Last Updated: February 13, 2017
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on June 27, 2017